New hope for kids with rare brain clots: blood thinner pill tested
NCT ID NCT07523347
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared the safety and effectiveness of the oral blood thinner rivaroxaban against standard anticoagulants in 75 children (ages 2 months to 18 years) with cerebrosinovenous thrombosis (CSVT), a rare type of brain vein clot. The goal was to see if rivaroxaban could normalize blood flow in the veins without causing dangerous bleeding. The study is completed, but results are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBROSINOVENOUS THROMBOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Children's Hospital
Lahore, Punjab Province, 54600, Pakistan